Tools
Stock profile

Edwards Lifesciences Corp (EW)

EW · Latest close $105.23 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$105.23
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
4
vs previous quarter

Edwards Lifesciences Corp (EW) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $10.9M sold). Latest close $105.23 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-10.9M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Wedgewood Partners · Mirova US · OrbiMed Advisors — 6 tracked funds hold EW. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 11 sales ($10.9M). Insider trading

Often held alongside

Syndax Pharmaceuticals Inc (SNDX) · O REILLY AUTOMOTIVE INC (ORLY) · BOSTON SCIENTIFIC CORP (BSX) · NEXTERA ENERGY INC (NEE) · ELI LILLY & Co (LLY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Wedgewood Partners3.08%165,208TRIMMED (-3.4%) Q3 filed Nov 16
Mirova US2.47%2,540,381TRIMMED (-3.3%) Q3 filed Nov 5
OrbiMed Advisors1.40%834,900TRIMMED (-32.2%) Q3 filed Nov 16
Torray Investment Partners LLC0.04%2,994HELD Q3 filed Oct 30
Deerfield Management0.01%13,702HELD Q3 filed Nov 16
Guinness Asset Management0.01%5,886ADDED (+27.2%) Q3 filed Nov 5
Viking Global Investors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +14.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

107.1565.472024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding1,334 of 8,857 filers
Long-only filers among them1,328
Change vs 2026 Q1+49 net · 1,132 entered · 1,083 exited
Shares reported, all filers519,669,388
Reported value, all filers$46.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Revenue · FY2025$6.1B
Net income · FY2025$1.1B
Total assets · FY2025$13.7B
Shares outstanding576,400,000
Market cap (at latest close)$60.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20269,333,399
Share of shares outstanding1.62%
Days to cover2.46

Shares short at recent settlements — Jul 31, 2026: 10.0M · Aug 14, 2026: 10.2M · Aug 31, 2026: 9.0M · Sep 15, 2026: 9.1M · Sep 30, 2026: 9.5M · Oct 15, 2026: 9.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 202618
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 74 · Oct 14, 2026: 18.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 11 sales by 7 insiders ($10.9M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 10, 2026Lippis Daniel J.CVP, TAVRSell619$104.25$64.5KSEC filing
Nov 9, 2026Zovighian Bernard JCEOSell9,184$103.39$949.5KSEC filing
Nov 9, 2026Zovighian Bernard JCEOSell13,916$102.78$1.4MSEC filing
Nov 9, 2026BOBO DONALD E JRCVP,Strategy/Corp DevelopmentSell48,900$103.05$5.0MSEC filing
Oct 8, 2026Lippis Daniel J.CVP, TAVRSell619$85.65$53.0KSEC filing
Sep 11, 2026Lippis Daniel J.CVP, TAVRSell619$87.51$54.2KSEC filing
Aug 31, 2026Dahl Andrew M.SVP, Corporate ControllerSell544$91.06$49.5KSEC filing
Aug 28, 2026Bruls AnnetteCVP, EMEACLASell2,644$89.98$237.9KSEC filing
Aug 26, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMSell1,154$91.76$105.9KSEC filing
Aug 26, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMSell30,646$90.99$2.8MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 31, 2026Dahl Andrew M.Officer544$49.5KAug 31, 2026SEC filing
Aug 28, 2026Bruls AnnetteOfficer2,644$237.9KAug 28, 2026SEC filing
Aug 26, 2026Markowitz WayneOfficer1,240$113.4KAug 26, 2026SEC filing
Aug 26, 2026Chopra DaveenOfficer31,800$2.9MAug 26, 2026SEC filing
Aug 11, 2026Lippis Daniel J.Officer1,857$170.9KAug 11, 2026SEC filing
Jul 30, 2026Ullem Scott B.Former Affiliate50,000$4.6MJul 30, 2026SEC filing
Jul 30, 2026Markowitz WayneOfficer147$12.6KJul 30, 2026SEC filing
Jul 28, 2026Markowitz WayneOfficer9,628$819.0KJul 28, 2026SEC filing
Jul 27, 2026Zovighian Bernard JOfficer, Director2,921$245.1KJul 27, 2026SEC filing
May 29, 2026Ullem Scott B.Former Affiliate64,152$5.6MMay 29, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 29, 2026Vanguard Capital ManagementSC 13G43,477,5337.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Oct 17, 2025BlackRock, Inc.SC 13G/A44,267,3767.5%Sep 30, 2025SEC filing
Aug 12, 2025Wellington Management Group LLPSC 13G/A19,826,4833.4%Jun 30, 2025SEC filing
Jan 30, 2025The Vanguard GroupSC 13G/A69,131,60211.7%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 327 Lobbying Disclosure Act filings named this company as client, 2004–2026; most common issues: Medicare/Medicaid (266), Health Issues (248), Taxation/Internal Revenue Code (134).

Federal contracts: $67.1M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$17.5M
FY2022$20.6M
FY2023$23.2M
FY2024$5.8M
FY2025$0
FY2026$0

Largest awards collected

Award IDAgencyAmountStart
36C24922P0612Department of Veterans Affairs$454.4KMay 27, 2022
36C25821P0209Department of Veterans Affairs$445.1KJun 8, 2021
0011Department of Defense$390.0KOct 1, 2016
36C24821P0717Department of Veterans Affairs$384.8KFeb 22, 2021
36C25622P1517Department of Veterans Affairs$358.5KSep 30, 2022

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Graham — Sound finances and a long run of profits

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· 52-Week High — Recently printed a new 52-week high

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Buffett — Latest ROE: 10.4% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 23.3% · Latest net income: $1.1B

· Graham — Current ratio: 3.72 · Straight profitable years: 18 · Debt ratio: 0.33 · Latest net income: $1.1B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Politician BEST — appeared in 2 of the last 20 quarterly lists; latest 2023 Q2, ranked #46 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together20.0%-8.4%+1.9%-10.2%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold EW — ranked by lift, the co-holding pattern described in Methodology: Syndax Pharmaceuticals Inc (SNDX) · O REILLY AUTOMOTIVE INC (ORLY) · BOSTON SCIENTIFIC CORP (BSX) · NEXTERA ENERGY INC (NEE) · ELI LILLY & Co (LLY) · THERMO FISHER SCIENTIFIC INC. (TMO).

Recent 8-K filings

FiledItemsSource
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 28, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Jul 23, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Syndax Pharmaceuticals Inc (SNDX) · Track Record: how the signals scored · Practice timing on EW

One email a week: the week’s new filings and research. Subscribe free

← EVTC  ·  EWBC →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.